dc.creator | Macías Sánchez, María Del Mar | es |
dc.creator | Morata Tarifa, Cynthia | es |
dc.creator | Cuende, Natividad | es |
dc.creator | Cardesa Gil, Ana | es |
dc.creator | Cuesta Casas, María Ángeles | es |
dc.creator | Pascual Cascon, María Jesús | es |
dc.creator | Pérez Simón, José Antonio | es |
dc.creator | Espigado Tocino, Ildefonso | es |
dc.creator | Sánchez Pernaute, Rosario | es |
dc.date.accessioned | 2022-11-22T15:59:31Z | |
dc.date.available | 2022-11-22T15:59:31Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Macías Sánchez, M.D.M., Morata Tarifa, C., Cuende, N., Cardesa Gil, A., Cuesta Casas, M.Á., Pascual Cascon, M.J.,...,Sánchez Pernaute, R. (2022). Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience. Stem Cells Translational Medicine, 11 (4), 343-355. https://doi.org/10.1093/stcltm/szac003. | |
dc.identifier.issn | 2157-6564 | es |
dc.identifier.issn | 2157-6580 | es |
dc.identifier.uri | https://hdl.handle.net/11441/139691 | |
dc.description.abstract | Graft versus host disease (GVHD) is a severe complication after allogenic hematopoietic cell transplantation (HSCT). Several clinical trials have re ported the use of mesenchymal stromal cells (MSCs) for the treatment of GVHD. In March 2008, the Andalusian Health Care System launched a
compassionate use program to treat steroid-resistant GVHD with MSC. Clinical-grade MSC were obtained under GMP conditions. MSC therapy
was administered intravenously in four separate doses of 1 × 106
cells/kg. Sixty-two patients, 45 males (7 children) and 17 females (2 children),
received the treatment. Patients had a median age of 39 years (range: 7–66) at the time of the allogenic HSCT. The overall response was achieved
in 58.7% of patients with acute (a)GVHD. Two years’ survival for aGVHD responders was 51.85%. The overall response for patients with chronic
(c)GVHD was 65.50% and the 2-year survival rate for responders was 70%. Age at the time of HSCT was the only predictor found to be inversely
correlated with survival in aGVHD. Regarding safety, four adverse events were reported, all recovered without sequelae. Thus, analysis of this
compassionate use experience shows MSC to be an effective and safe therapeutic option for treating refractory GVHD, resulting in a significant
proportion of patients responding to the therapy. | es |
dc.format | application/pdf | es |
dc.format.extent | 13 p. | es |
dc.language.iso | eng | es |
dc.publisher | WILEY | es |
dc.relation.ispartof | Stem Cells Translational Medicine, 11 (4), 343-355. | |
dc.rights | Atribución-NoComercial 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc/4.0/ | * |
dc.subject | Mesenchymal stromal cells | es |
dc.subject | Allogenic hematopoietic stem cell transplantation | es |
dc.subject | Graft versus host disease | es |
dc.subject | Cell therapy | es |
dc.title | Mesenchymal Stromal Cells for Treating Steroid-Resistant Acute and Chronic Graft Versus Host Disease: A Multicenter Compassionate Use Experience | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.publisherversion | https://academic.oup.com/stcltm/article/11/4/343/6550101 | es |
dc.identifier.doi | 10.1093/stcltm/szac003 | es |
dc.journaltitle | Stem Cells Translational Medicine | es |
dc.publication.volumen | 11 | es |
dc.publication.issue | 4 | es |
dc.publication.initialPage | 343 | es |
dc.publication.endPage | 355 | es |